{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-077200","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.892386+00:00","generated_at":"2026-05-17T13:53:40.145310+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sagimet Q2 net loss $10.4M, cash $135.5M; denifanstat meets all acne Phase 3 endpoints","bullets":["Net loss Q2 2025 $10.4M vs $8.1M; H1 loss $28.6M vs $14.7M; R&D and G&A both increased.","Cash position $135.5M at June 30, 2025; no revenue reported (pre-revenue biotech).","Denifanstat Phase 3 acne trial (Ascletis) met all endpoints: treatment success 33.2% vs 14.6% (p<0.0001).","Initiated Phase 1 for TVB-3567 (acne) in U.S.; combo trial denifanstat+resmetirom PK study planned 2H 2025 with readout 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-077200","json":"https://secwatch.observer/filing/0001104659-25-077200.json","markdown":"https://secwatch.observer/filing/0001104659-25-077200.md","text":"https://secwatch.observer/filing/0001104659-25-077200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/0001104659-25-077200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:53:40.145310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}